



We, LTT Bio-Pharma, have been applying cutting-edge science and technology to medicine for more than 30 years, have been conducting research and development to protect the health and lives of people all over the world.
Research and Development
We will introduce our original drug discovery technologies, pipeline under development, and launched drugs.
DR
Drug Repositioning
We were the first in Japan to point out the importance of DR and have been promoting drug discovery as a leading
DR company. We are also engaged in collaborative research using our own original library of approved drugs.


DDS
Drug Delivery System
Like DR, DDS contributes to early commercialization and reduced development risk. We have launched DDS new drug and are still developing new drugs using the world’s first DDS technology.
Collaborative R&D
and Consultation
Through joint development, we connect academia and pharmaceutical companies to efficiently develop pharmaceuticals.

Founding Family
創業者と創業家 / 水島徹 & 水島広子

Corporate Information
Careers
IR Information
- All
- Business Development
- Drug Discovery
- General Meeting of Shareholders
- Financial Information
- Other
-
2025.09.11
Report on the Conduct of the PC-SOD Phase III Clinical Trial Investigator Meeting
-
2025.09.10
Request for notification of changes to shareholder register entries, such as address changes
-
2025.08.21
Announcement Regarding Initiation of Phase III Clinical Trial of PC-SOD for CIPN
-
2025.08.06
Negotiations with European pharmaceutical company regarding PC-SOD license agreement
-
2025.09.11
Report on the Conduct of the PC-SOD Phase III Clinical Trial Investigator Meeting
-
2025.08.21
Announcement Regarding Initiation of Phase III Clinical Trial of PC-SOD for CIPN
-
2025.07.31
Notice Regarding the Conclusion of a Joint Research Agreement
-
2025.07.23
Announcement of Joint Research Agreement with Yamaguchi University
-
2025.06.25
Notice of Resolutions of the 23rd Ordinary General Meeting of Shareholders
-
2025.06.05
Partial correction of the contents of the” Announcement of the 23rd Ordinary General Meeting of Shareholders”
-
2025.06.05
Announcement of the 23rd Ordinary General Meeting of Shareholders
-
2025.03.18
Notice of Resolutions of the 22nd Ordinary General Meeting of Shareholders
-
2025.09.10
Request for notification of changes to shareholder register entries, such as address changes
-
2025.05.29
Announcement of our CEO’s appointment as a director of the SAMURAI Biotech Association
-
2025.05.21
Meeting with Mr. Tse Ping, founder of Sino Biopharmaceutical Limited and Vice Chairman of our Board of Directors, and our CEO
-
2025.05.13
Request for notification of changes to shareholder register entries, such as address changes
